Janney Montgomery Scott LLC Increases Holdings in Moderna, Inc. (NASDAQ:MRNA)

Janney Montgomery Scott LLC boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 6.3% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,767 shares of the company’s stock after buying an additional 756 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Moderna were worth $853,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Ashton Thomas Private Wealth LLC bought a new position in Moderna during the second quarter valued at $26,000. Family Firm Inc. purchased a new position in shares of Moderna during the 2nd quarter valued at $33,000. Cedar Wealth Management LLC grew its stake in shares of Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the period. Bank & Trust Co purchased a new stake in Moderna in the 2nd quarter worth about $36,000. Finally, Hanseatic Management Services Inc. bought a new stake in Moderna in the 2nd quarter valued at about $48,000. Institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the subject of several recent research reports. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 target price for the company in a research note on Wednesday, August 28th. Bank of America reduced their price objective on shares of Moderna from $130.00 to $110.00 and set a “neutral” rating for the company in a research note on Friday, September 13th. UBS Group dropped their target price on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Barclays cut their price target on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a report on Friday, November 8th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $75.00 price objective on shares of Moderna in a research note on Thursday, September 19th. Three equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $90.22.

Moderna Price Performance

MRNA stock opened at $36.85 on Friday. The firm has a 50 day simple moving average of $58.56 and a two-hundred day simple moving average of $96.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The stock has a market cap of $14.18 billion, a PE ratio of -6.33 and a beta of 1.69. Moderna, Inc. has a one year low of $35.80 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the business posted ($1.39) earnings per share. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. On average, analysts predict that Moderna, Inc. will post -9.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. This represents a 13.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 2,930 shares of company stock valued at $217,170 over the last quarter. 15.70% of the stock is owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.